β2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7294-7305

  Nomura, Takeo ^a,b   Huang, Wen Chin ^a   Zhau, Haiyen E ^a   Wu, Daqing ^a   Xie, Zhihui ^a   Mimata, Hiromitsu ^b   Zayzafoon, Majd ^c   Young, Andrew N ^a   Marshall, Fray F ^a   Weitzmann, M Neale ^a   Chung, Leland W K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OITA UNIVERSITY   (Japan)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN; ONCOPROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CANCER INVASION; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BETA 2-MICROGLOBULIN; CARCINOMA, RENAL CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846261554     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2060     Document Type: Article

References (50)

1. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990;59:253-88.
2. Ploegh HL, Orr HT, Strominger JL. Major histocompatiblity antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell 1981;24:287-99.
3. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 1996;272:67-74.
4. Salter RD, Benjamin RJ, Wesley, et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 1990;345:41-6.
5. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-9.
6. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996;13:210-3.
7. Amiot L, Onno M, Lamy T, et al. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998;100:655-63.
8. 2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998;101:2720-9.
9. Rowley DR, Dang TD, McBride L, Gerdes MJ, Lu B, Larsen M. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res 1995;55:781-6.
10. Abdul M, Hoosein N. Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 2000;5:168-72.
11. Solheim JC. Class I MHC molecules: assembly and antigen presentation. Immunol Rev 1999;172:11-9.
12. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999;13:1295-314.
13. Nissen MH, Bjerrum OJ, Plesner T, Wilken M, Rorth M. Modification of beta-2-microglobulin in sera from patients with small cell lung cancer: evidence for involvement of a serine protease. Clin Exp Immunol 1987;67:425-32.
14. Rasmuson T, Grankvist K, Ljungberg B. Serum beta 2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncol 1996;35:479-82.
15. Mavridis AK, Tsiara S, Makis A, et al. TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia. J Exp Clin Cancer Res 1998;17:445-8.
16. Sadamori N, Mine M, Hakariya S, et al. Clinical significance of beta-2-microglobulin in serum of adult T cell leukemia. Leukemia 1995;9:594-7.
17. Gressner AM, Neu HH. N-terminal procollagen peptide and beta 2-microglobulin in synovial fluids from inflammatory and non-inflammatory joint diseases. Clin Chim Acta 1984;141:241-5.
18. 2-microglobulin levels in urological cancer. J Urol 1979;121:624-5.
19. Naito S, Walker SM, Fidler IJ. In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis 1989;7:381-9.
20. Passaniti A, Isaacs JT, Haney JA, et al. Stimulation of human prostatic carcinoma tumor growth in athymic nude mice and control of migration in culture by extracellular matrix. Int J Cancer 1992;51:318-24.
21. Inoue K, Karashima T, Fukata S, et al. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res 2005;11:6669-77.
22. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845-52.
23. Arrington SA, Schoonmaker JE, Damron TA, Mann KA, Allen MJ. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone 2006;38:359-67.
24. Buszello H, Ackermann R. Expression of HLA class-I antigens on renal cell carcinoma and non-transformed renal tissue. Eur Urol 1992;21:70-4.
25. Buszello H, Ackermann R. Immunohistochemical studies on the expression of HLA class I antigens in renal cell carcinoma: comparison of primary and metastatic tumor tissue. Eur Urol 1994;25:158-63.
26. Gastl G, Ebert T, Finstad CL, et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 1996;155:361-7.
27. 2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 2006;66:9108-16.
28. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 1985;52:1-6.
29. Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment - a prospective study of 160 patients. Blood 1984;63:468-76.
30. 2-Microglobulin identified as an apoptosis-inducing factor and its characterization. Blood 1999;94:2744-53.
31. 2- Microglobulin as a negative growth regulator of myeloma cells. Br J Haematol 2002;118:495-505.
32. 2- microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006;10:295-307.
33. Al-Wadei HA, Takahashi T, Schuller HM. Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer 2006;118:1370-80.
34. Huang W-C, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LWK. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005;65:2303-13.
35. Shanker DB, Cheng JC, Sakamoto KM. Role of cyclic AMP response element binding protein in human leukemias. Cancer 2005;104:1819-24.
36. Abramovitch R, Tavor E, Jacob-Hirsch J, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res 2004;64:1338-46.
37. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
38. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
39. Thakker GD, Hajjars DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999;274:10002-7.
40. Kwon EM, Raines MA, Blenis J, Sakamoto KM. Granulocyte-macrophage colony-stimulating factor stimulation results in phosphorylation of cAMP response element-binding protein through activation of pp90RSK. Blood 2000;95:2552-8.
41. Joo EK, Broxmeyer HE, Kwon HJ, et al. Enhancement of cell survival by stromal cell-derived factor-1/CXCL12 involves activation of CREB and induction of Mcl-1 and c-Fos in factor-dependent human cell line MO7e. Stem Cells Dev 2004;13:563-70.
42. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002;14:381-95.
43. Jubb AM, Pham TQ, Handy AM. Expression of vascular endothelial growth factor, hypoxia inducible factor 1 alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 2004;58:335-6.
44. Frangou EM, Lawson J, Kanthan R. Angiogenesis in male breast cancer. World J Surg Oncol 2005;3:16.
45. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27.
46. Fureder W, Krauth M-T, Sperr WR, et al. Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am J Pathol 2006;168:123-30.
47. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999;190:293-8.
48. Yao S, Liu D, Pan F, Wise GE. Effect of vascular endothelial growth factor on RANK gene expression in osteoclast precursors and on osteoclastogenesis. Arch Oral Biol 2006;51:596-602.
49. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
50. Aldridge SE, Lennard TWJ, Williams JR, Birch MA. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 2005;92:1531-7.